Home › Infertility › NCT02357654

GnRH for Luteal Support in IVF/ICSI/FET Cycles

Who can join

Ages 18 to 40 · Women

Inclusion Criteria:

* women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.

Exclusion Criteria:

* day 3 transfers

About the study

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .

What is being tested

• GnRH (drug)
• placebo (drug)

Sponsor: University Reproductive Associates · Participants: 350 · Started: 2015-11

Contact the study team

• Peter G McGovern, MD · Phone: 201-288-6330

Official record on ClinicalTrials.gov — NCT02357654

Locations in the U.S.

Conditions

• Infertility

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.